Study summary

Nearly half of people with follicular lymphoma were still lymphoma-free 10 years after CAR T-cell therapy

Penn CAR T-cell 10-year follow-up · 38 people (14 with follicular lymphoma), early-phase study · Published June 2026, New England Journal of Medicine

47%lymphoma-free at 10 years (follicular lymphoma)

What was tested

Ten-year follow-up of the first patients treated with tisagenlecleucel (CAR T cells aimed at CD19) for relapsed large B-cell or follicular lymphoma at the University of Pennsylvania.

What they found

10-year lymphoma-free survival was 47% in follicular lymphoma and 32% in large B-cell lymphoma.
No relapses occurred after 5.4 years.
10-year survival was 50% in follicular lymphoma.

What it means

The longest follow-up of CAR T-cell therapy; suggests a one-time treatment can produce lasting remissions.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.